AGM/EGMJun 8, 2026, 04:07 PM
Jazz Pharmaceuticals Announces 2026 Annual General Meeting Details
AI Summary
Jazz Pharmaceuticals plc has filed its Definitive Proxy Statement for the 2026 Annual General Meeting of Shareholders (AGM), scheduled for July 23, 2026, in Dublin, Ireland. The meeting agenda includes the election of three director nominees, ratification of KPMG as independent auditors, an advisory vote on executive compensation, and proposals to grant the board authority to allot and issue ordinary shares. The record date for shareholders eligible to vote is May 28, 2026.
Key Highlights
- Jazz Pharmaceuticals plc will hold its 2026 Annual General Meeting of Shareholders on July 23, 2026, in Dublin, Ireland.
- Shareholders will vote on the election of three director nominees: Bruce C. Cozadd, Heather Ann McSharry, and Rick E Winningham.
- The appointment of KPMG as independent auditors for fiscal year 2026 will be ratified on a non-binding advisory basis.
- Shareholders will vote on a non-binding advisory basis to approve the compensation of named executive officers.
- The board is seeking authority to allot and issue ordinary shares and to allot and issue shares for cash without first offering them to existing shareholders.
Price Impact
More from JAZZ